BDMD
Baird Medical Investment Holdings Limited (BDMD) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
A current ratio of 1.29 and quick ratio of 1.26 indicate near-term liquidity coverage, though peers with stronger balance sheets retain more flexibility.
Debt-to-equity of 0.41 suggests leverage is contained versus more indebted peers, limiting refinancing pressure and preserving optionality.
Net debt to EBITDA of -1.07 implies net cash positioning, which is structurally stronger than leveraged peers and supports resilience through demand volatility.
Weaknesses
Return on invested capital of -26.96% signals capital is destroying value, leaving BDMD structurally behind peers that generate positive returns on deployed capital.
Cash conversion cycle of 425.3 days indicates severe working-capital drag, tying up cash far longer than peers and constraining reinvestment capacity.
Liquidity ratios above 1.0 are only modestly adequate, so BDMD has less operating cushion than stronger peers if collections slow or costs rise.
Opportunities
Reducing the 425.3-day cash conversion cycle would release trapped working capital, improving liquidity and narrowing the gap with peers that convert cash faster.
If management improves capital efficiency, negative ROIC could move toward peer norms, which would materially strengthen long-term positioning and valuation support.
Net cash balance sheet capacity could be redeployed into higher-return initiatives, giving BDMD more flexibility than leveraged peers to fund operational improvements.
Threats
Persistent negative ROIC increases the risk that peers with better capital discipline will compound market share and profitability advantages over time.
An exceptionally long cash conversion cycle heightens exposure to customer delays and inventory misalignment, making BDMD more fragile than faster-converting peers.
If working-capital needs remain elevated, even modest demand weakness could pressure liquidity more than at peers with stronger cash generation.
Overall Score
BDMD’s net cash position provides some balance-sheet support, but deeply negative ROIC and extreme working-capital inefficiency leave its structural positioning below peers.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Baird Medical Investment Holdings Limited. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
